Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • RAMM Pharma (RAMM) has started trials to study the efficacy of its pet cannabinoid formulation
  • The company hopes to use its proprietary NettaVet for treatment of four pathologies in animals
  • The trials will be conducted in partnership with Universidad de la Republica de Uruguay
  • The treatment covers three conditions pertaining to dogs, and one to horses
  • RAMM Pharma is down 3.85 per cent, with shares of the company trading at C$1.00 at 10:56 am ET

RAMM Pharma (RAMM) has started trials to study the efficacy of its pet cannabinoid formulation.

The company hopes to use its proprietary NettaVet for treatment of four pathologies in animals.

The trials will be conducted in partnership with Universidad de la Republica de Uruguay.

Experts from Montreal University, the University of Buenos Aires, São Paulo State University and the University of Barcelona will also be involved.

The clinical trials will evaluate the efficacy of the cannabinoid formulations for the treatment of anxiety in dogs, chronic osteoarthritis pain in dogs, allergic dermatitis in dogs and chronic osteoarthritis pain in horses.

NettaLife is a wholly-owned subsidiary of RAMM, dedicated to the production, export and commercialization of pet products, food, pharmaceutical specialties and cosmetic products for animals.

“We are pleased to commence this initial set of clinical trials with renowned experts to advance the development of products to help address some of the most common animal ailments,” said RAMM Pharma Corp. CEO Jack Burnett.

RAMM Pharma is down 3.85 per cent, with shares of the company trading at C$1.00 at 10:56 am ET.

More From The Market Herald

" Nutritional High’s (CSE:EAT) California businesses aided by new ordinance vote

Nutritional High’s (EAT) OutCo acquisition will benefit from a recent vote by the San Diego County Board of Supervisors.

" VIVO Cannabis™ (TSX:VIVO) completes first shipment to Beacon Medical Germany GmbH

VIVO Cannabis’s (VIVO) subsidiary ABcann Medicinals has completed its first shipment of EU-GMP certified Canadian dried flower medical cannabis into Europe.
BioHarvest Sciences - David Tsur

" BioHarvest Sciences (CSE:BHSC) appoints David Tsur to its board of directors

BioHarvest Sciences (BHSC) has announced that, effective immediately, David Tsur will serve as a non-executive director of the company.

" Maple Leaf Green World (CSE:MGW) unveils new CBG wellness brand

Maple Leaf Green World (MGW) is launching a new health and wellness brand, RèNao Wellness.